Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.95
-0.05 (-0.83%)
Apr 20, 2026, 4:08 PM HKT
Sino Biopharmaceutical Revenue
In the year 2025, Sino Biopharmaceutical had annual revenue of 31.83B CNY with 10.28% growth. Sino Biopharmaceutical had revenue of 14.26B in the half year ending December 31, 2025.
Revenue
31.83B CNY
Revenue Growth
+10.28%
P/S Ratio
3.00
Revenue / Employee
1.49M CNY
Employees
21,435
Market Cap
106.31B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.83B | 2.97B | 10.28% |
| Dec 31, 2024 | 28.87B | 2.67B | 10.18% |
| Dec 31, 2023 | 26.20B | 173.25M | 0.67% |
| Dec 31, 2022 | 26.03B | -835.19M | -3.11% |
| Dec 31, 2021 | 26.86B | 3.21B | 13.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 41.59B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.62B |
| Akeso | 3.40B |
| Shanghai Junshi Biosciences | 2.78B |
Sino Biopharmaceutical News
- 6 weeks ago - Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln - Reuters
- 2 years ago - Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln - Reuters
- 5 years ago - Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea - Forbes